help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fraher, L. J.
Right arrow Articles by Goltzman, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fraher, L. J.
Right arrow Articles by Goltzman, D.

Journal of Clinical Endocrinology & Metabolism, Vol 75, 417-423, Copyright © 1992 by Endocrine Society


ARTICLES

A comparison of the in vivo biochemical responses to exogenous parathyroid hormone-(1-34) [PTH-(1-34)] and PTH-related peptide-(1-34) in man

LJ Fraher, AB Hodsman, K Jonas, D Saunders, CI Rose, JE Henderson, GN Hendy and D Goltzman
Department of Medicine, Lawson Research Institute, St. Joseph's Health Centre, London, Ontario, Canada.

PTH-related peptide (PTHrP) is one of the etiological factors associated with hypercalcemia of malignancy in humans and rodents. In both in vivo and in vitro animal systems its actions mimic those of PTH; however, its bioactivity in humans has not previously been assessed. Therefore, we compared the actions of the synthetic human (h) analogs hPTHrP-(1-34) and hPTH-(1-34) when given by iv infusion to 15 healthy subjects, aged 25 +/- 3 yr. Three 12-h test infusions were given to each subject in the order: hPTH-(1-34) at a dose of 8 pmol/kg.h, an equimolar dose (8 pmol/kg.h) of PTHrP-(1-34) (low dose), and a 10-fold higher dose (80 pmol/kg.h) of hPTHrP-(1-34) (high dose). PTH infusion resulted in significant increases from basal values in serum total ionized calcium, urinary phosphate and cAMP, and serum 1,25- dihydroxyvitamin D3 [1,25-(OH)2d3]. No significant increases from basal values in any of these variables were observed during low dose PTHrP infusion. However, a 10-fold higher dose of PTHrP significantly increased serum calcium from 2.36 +/- 0.07 to 2.63 +/- 0.16 mmol/L (P less than 0.003), ionized calcium from 1.22 +/- 0.03 to 1.39 +/- 0.09 mmol/L (P less than 0.003), urinary phosphate from 0.21 +/- 0.19 to 0.31 +/- 0.16 mmol/L glomerular filtrate (P less than 0.05), urinary cAMP from 37 +/- 18 to 53 +/- 28 nmol/L glomerular filtrate (P less than 0.01), and serum 1,25-(OH)2D3 from 29.8 +/- 12.1 to 46.0 +/- 20.3 pmol/L (P less than 0.01). For each variable these changes were statistically equivalent to the increases observed during PTH infusion. The molar concentrations of circulating immunoreactive PTH-(1-34) and PTHrP-(1-34) (at the higher dose) achieved during infusion were at a ratio of 1:3. These results suggest that the in vivo actions of synthetic hPTHrP-(1-34) are comparable to those of hPTH-(1-34), but its biological activity after infusion may be less than that of hPTH-(1- 34). Moreover, the increased concentrations of serum 1,25-(OH)2D3 observed with administration of hPTHrP-(1-34) are unlike the changes seen in hypercalcemia of malignancy in which levels of this vitamin D metabolite are frequently depressed.


This article has been cited by other articles:


Home page
J EndocrinolHome page
G. S Bevelander, E. S L C Pinto, A. V M Canario, T. Spanings, and G. Flik
CYP27A1 expression in gilthead sea bream (Sparus auratus, L.): effects of calcitriol and parathyroid hormone-related protein
J. Endocrinol., March 1, 2008; 196(3): 625 - 635.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. J. Horwitz, M. B. Tedesco, S. M. Sereika, B. W. Hollis, A. Garcia-Ocana, and A. F. Stewart
Direct Comparison of Sustained Infusion of Human Parathyroid Hormone-Related Protein-(1-36) [hPTHrP-(1-36)] Versus hPTH-(1-34) on Serum Calcium, Plasma 1,25-Dihydroxyvitamin D Concentrations, and Fractional Calcium Excretion in Healthy Human Volunteers
J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1603 - 1609.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. A. Syed, M. J. Horwitz, M. B. Tedesco, A. Garcia-Ocaña, S. R. Wisniewski, and A. F. Stewart
Parathyroid Hormone-Related Protein-(1-36) Stimulates Renal Tubular Calcium Reabsorption in Normal Human Volunteers: Implications for the Pathogenesis of Humoral Hypercalcemia of Malignancy
J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1525 - 1531.
[Abstract] [Full Text]


Home page
Proc. Natl. Acad. Sci. USAHome page
W. Huang, U.-i. Chung, H. M. Kronenberg, and B. de Crombrugghe
The chondrogenic transcription factor Sox9 is a target of signaling by the parathyroid hormone-related peptide in the growth plate of endochondral bones
PNAS, December 19, 2000; (2000) 11393998.
[Abstract] [Full Text]


Home page
Am. J. Physiol. Renal Physiol.Home page
M. Mannstadt, H. Juppner, and T. J. Gardella
Receptors for PTH and PTHrP: their biological importance and functional properties
Am J Physiol Renal Physiol, November 1, 1999; 277(5): F665 - F675.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
L. J. Fraher, R. Avram, P. H. Watson, G. N. Hendy, J. E. Henderson, K. L. Chong, D. Goltzman, P. Morley, G. E. Willick, J. F. Whitfield, et al.
Comparison of the Biochemical Responses to Human Parathyroid Hormone-(1-31)NH2 and hPTH-(1-34) in Healthy Humans
J. Clin. Endocrinol. Metab., August 1, 1999; 84(8): 2739 - 2743.
[Abstract] [Full Text]


Home page
Endocr. Rev.Home page
T. A. Guise and G. R. Mundy
Cancer and Bone
Endocr. Rev., February 1, 1998; 19(1): 18 - 54.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
M. Wolzt, L. Schmetterer, G. Dorner, G. Zelger, J. Entlicher, S. Kapiotis, and H.-G. Eichler
Hemodynamic Effects of Parathyroid Hormone-Related Peptide-(1-34) in Humans
J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2548 - 2551.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
J. G. Henry, M. Mitnick, P. R. Dann, and A. F. Stewart
Parathyroid Hormone-Related Protein-(1-36) Is Biologically Active When Administered Subcutaneously to Humans
J. Clin. Endocrinol. Metab., March 1, 1997; 82(3): 900 - 906.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. B. Hodsman, L. J. Fraher, P. H. Watson, T. Ostbye, L. W. Stitt, J. D. Adachi, D. H. Taves, and D. Drost
A Randomized Controlled Trial to Compare the Efficacy of Cyclical Parathyroid Hormone Versus Cyclical Parathyroid Hormone and Sequential Calcitonin to Improve Bone Mass in Postmenopausal Women with Osteoporosis
J. Clin. Endocrinol. Metab., February 1, 1997; 82(2): 620 - 628.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
E. B. Mawer, J. Walls, A. Howell, M. Davies, W. A. Ratcliffe, and N. J. Bundred
Serum 1,25-Dihydroxyvitamin D May Be Related Inversely to Disease Activity in Breast Cancer Patients with Bone Metastases
J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 118 - 122.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
W. Huang, U.-i. Chung, H. M. Kronenberg, and B. de Crombrugghe
The chondrogenic transcription factor Sox9 is a target of signaling by the parathyroid hormone-related peptide in the growth plate of endochondral bones
PNAS, January 2, 2001; 98(1): 160 - 165.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1992 by The Endocrine Society